Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAMK2G is identified as a novel therapeutic target for myelofibrosis.

Blood advances - 8 Mar 2022

Miyauchi Masashi, Sasaki Ken, Kagoya Yuki, Taoka Kazuki, Masamoto Yosuke, Yamazaki Sho, Arai Shunya, Mizuno Hideaki, Kurokawa Mineo

Abstract excerpt

Although JAK1/2 inhibition is effective in alleviating symptoms of myelofibrosis (MF), it does not result in the eradication of MF clones, which can lead to inhibitor-resistant clones emerging during the treatment. Here, we established induced pluripotent stem cells (iPSCs) derived from MF patient samples (MF-iPSCs) harboring JAK2 V617F, CALR type 1, or CALR type 2 mutations. We demonstrated that these cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Calcium-Calmodulin-Dependent Protein Kinase Type 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Phenotype

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Source

Open in PubMed Open full text

Identifiers

PMID: 34521112
DOI: 10.1182/bloodadvances.2020003303
PMCID: PMC8905705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

CAMK2G is identified as a novel therapeutic target for myelofibrosis.PMID 34521112Read ↗

Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.Semantic proximity Read ↗

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read ↗

CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.Semantic proximity Read ↗

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Semantic proximity Read ↗

Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling.Semantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.Semantic proximity Read ↗

Structure-guided synthesis of FK506 and FK520 analogs with increased selectivity exhibit in vivo therapeutic efficacy against CryptococcusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.